Canon Inc. Overview
Canon Inc. is a ¥4.6 trillion Japanese technology conglomerate. Its roots are in optics and precision engineering, which it has extended into four industry-facing groups: Printing, Medical, Imaging and Industrial. Office and production printing still provide more than half of revenue and most of the cash flow. Growth now comes from mirrorless and network cameras, diagnostic imaging, and a semiconductor-equipment franchise that has gained strategic weight as AI-driven memory and advanced-packaging investment rises. In semiconductor manufacturing, Canon is the world's leading supplier of i-line lithography steppers and a major KrF scanner vendor. It also makes FPD lithography systems, OLED evaporation lines (Canon Tokki), sputtering and deposition tools (Canon Anelva) and die bonders. It is commercialising nanoimprint lithography (NIL) as a lower-cost path to leading-edge patterning. Canon also supports the installed base of its steppers through refurbishment, relocation and spare-parts programmes, which place it squarely in the semiconductor equipment refurbishment ecosystem. Founder-era continuity remains distinctive: Fujio Mitarai has led the company for most of the past three decades. Under the Phase VII plan (2026–2030), management is pursuing productivity-led growth toward ¥5.6 trillion of sales and a 15% operating margin by 2030.
What the company does
Canon designs, manufactures, sells and services imaging, printing, medical and industrial equipment worldwide. The FY2025 Annual Securities Report organises the business into four reportable segments plus "Others and Corporate":
Printing: digital continuous-feed and sheet-fed production presses, large-format printers, office multifunction devices (MFDs), laser and inkjet printers, image scanners and calculators.
Medical: CT, MRI, diagnostic ultrasound, diagnostic X-ray, digital radiography, ophthalmic equipment, in-vitro diagnostic systems and reagents, and healthcare IT.
Imaging: interchangeable-lens and compact digital cameras, interchangeable lenses, network cameras, video-management and video-analytics software, camcorders, cinema cameras and broadcast equipment.
Industrial: semiconductor lithography equipment, FPD lithography equipment, OLED display manufacturing equipment, vacuum thin-film deposition equipment and die bonders.
Others and Corporate: handy terminals, document scanners and other businesses, including the space business developed through Canon Electronics.
Business and revenue model
Canon's model combines hardware sales with recurring revenue, and the mix differs sharply by segment:
Printing: is a classic installed-base model. Device placements (MFDs, laser printers, inkjet printers, production presses) generate long-tail revenue from toner, ink, maintenance contracts, managed print services and document-workflow software. Consumables and service ("non-hardware") are the main profit pool. Sell-in of hardware is the leading indicator of future annuity revenue.
Medical: sells capital equipment (CT, MRI, ultrasound, X-ray) to hospitals and imaging centres, mostly built to order, together with multi-year service contracts, IVD reagents and healthcare IT.
Imaging: is mainly product sales: camera bodies, lenses and network cameras. A growing software and licence layer comes through Axis (network video) and Milestone Systems (video management software, VMS).
Industrial: sells capital equipment to semiconductor, display and electronics manufacturers. Lithography revenue depends on unit shipments and mix (KrF scanners sell at higher prices than i-line steppers), followed by installation, field service, spare parts, upgrades and refurbishment over each tool's multi-decade life.
Canon does not publish a formal split of product, service, subscription and licensing revenue. Its own commentary consistently treats consumables, maintenance and services in Printing, and service contracts in Medical, as the core of recurring revenue. Intellectual property also produces licensing income: Canon ranked seventh worldwide by U.S. patents granted in 2025, with 2,623 patents.
Value-chain position
Canon is unusually vertically integrated. It develops and makes its own optical glass and lenses, CMOS image sensors, inkjet printheads, toner, and many key components and production machines (the latter through Canon Semiconductor Equipment Inc. and other units). In semiconductors it is an equipment supplier (Tier 1 tool OEM) to chipmakers and to OSATs and advanced-packaging houses. It is not a chip producer for third parties, although it makes sensors for its own products.
Customer types and end-markets
| Segment | Principal customers | End-markets served |
|---|---|---|
| Printing | Corporates, SMBs, governments, print service providers, publishers, packaging converters, consumers | Office document output, commercial and transactional printing, book printing, signage and graphics, home printing |
| Medical | Hospitals, clinics, imaging centres, laboratories, research institutes | Diagnostic imaging, in-vitro diagnostics, healthcare IT |
| Imaging | Consumers, creators, professional photographers, broadcasters, cinema producers, security integrators, municipalities, retailers | Consumer and professional photography, video and cinema, physical security and video analytics |
| Industrial | Memory, logic, power, sensor and MEMS chipmakers; OSATs; display panel makers; electronics manufacturers | Front-end semiconductor lithography, advanced packaging, FPD lithography, OLED deposition, thin-film deposition (including HBM-related), die bonding |
Printing: Principal customers: Corporates, SMBs, governments, print service providers, publishers, packaging converters, consumers; End-markets served: Office document output, commercial and transactional printing, book printing, signage and graphics, home printing
Medical: Principal customers: Hospitals, clinics, imaging centres, laboratories, research institutes; End-markets served: Diagnostic imaging, in-vitro diagnostics, healthcare IT
Imaging: Principal customers: Consumers, creators, professional photographers, broadcasters, cinema producers, security integrators, municipalities, retailers; End-markets served: Consumer and professional photography, video and cinema, physical security and video analytics
Industrial: Principal customers: Memory, logic, power, sensor and MEMS chipmakers; OSATs; display panel makers; electronics manufacturers; End-markets served: Front-end semiconductor lithography, advanced packaging, FPD lithography, OLED deposition, thin-film deposition (including HBM-related), die bonding
Independent characterisation
Canon is best understood as a cash-generative printing annuity that funds a portfolio of optical-technology growth businesses. Three of those businesses now matter most to the investment case. Network video (Axis/Milestone) is structurally growing. Medical imaging is a turnaround: Canon took a ¥165.1 billion goodwill impairment in FY2024 and then folded Canon Medical Systems into the parent company in April 2026. Semiconductor lithography is small in revenue terms (Industrial was 7.8% of FY2025 sales) but very profitable and strategically valuable, because Canon supplies the mature-node i-line and KrF tools that memory, power, image-sensor and advanced-packaging fabs need in volume. Canon also runs refurbishment programmes for its own photolithography tools, which keeps its legacy installed base (for example the FPA-3000 series) productive in 150 mm and 200 mm fabs. That puts Canon in direct competition with third-party refurbishers such as Ventex in the semiconductor-equipment refurbishment services market.
Strategy
Stated strategy: Excellent Global Corporation Plan Phase VII (2026–2030)
The plan's basic policy is to "Achieve new growth through innovations in productivity." The main themes in the FY2025 Annual Securities Report and the January 2026 Phase VII conference are:
-
Three structural reforms
-
Sales reform: restructure European sales channels (to be completed by 2028), building on the 2024–2025 U.S. channel and DX overhaul.
-
Production reform: concentrate in-house manufacturing on high-value products, consolidate overseas sites (about 60 under review), and use automation to bring production back to Japan.
-
Medical business innovation: integrate Canon Medical Systems into the parent company (done April 2026) and apply Canon's quality-control and cost-reduction methods to medical development, manufacturing and management.
-
-
Printing: strengthen the electrophotographic and inkjet platforms, add AI-driven services, and push further into commercial and industrial printing. The Heidelberg OEM alliance supports the sheet-fed inkjet push.
-
Medical: focus on diagnostic imaging (photon-counting CT, AI diagnostic support), in-vitro diagnostics, and regenerative-medicine research.
-
Imaging: broaden camera and lens lineups and grow network video through Axis and Milestone.
-
Industrial: expand lithography (including nanoimprint) and film deposition, and pursue M&A.
-
Cross-group: grow AI-based solutions and software and service revenue, and develop a mid- to long-term space business.
Medium-term financial targets
| Metric | FY2025 actual | 2026 target | 2028 target | 2030 target |
|---|---|---|---|---|
| Net sales (¥ bn) | 4,624.7 | 4,765.0 | 5,000.0 | 5,600.0 |
| Operating margin (%) | 9.8 | 10.0 | 12.0 | 15.0 |
| ROE (%) | 9.7 | 10.0 | 12.0 | 15.0 |
Net sales (¥ bn): FY2025 actual: 4624.7; 2026 target: 4765.0; 2028 target: 5000.0; 2030 target: 5600.0
Operating margin (%): FY2025 actual: 9.8; 2026 target: 10.0; 2028 target: 12.0; 2030 target: 15.0
ROE (%): FY2025 actual: 9.7; 2026 target: 10.0; 2028 target: 12.0; 2030 target: 15.0
The 2026 target column shows the original January 2026 guidance. After the October 2026 revision Canon projects 2026 sales of ¥4,766.0 billion, an operating margin of 9.6% and ROE of 9.6%. Management states a WACC of 5–6% and a payout-ratio target of about 40%.
Initiatives announced in the last 24 months
| Date | Initiative | Detail / targets |
|---|---|---|
| FY2024–FY2026 | Structural reform programme | Sales reform cost ¥22.0 billion in FY2025 and ¥17.2 billion in FY2026, with a ¥11.5 billion benefit expected in 2026. Production reform cost ¥14.7 billion in FY2025 and ¥14.2 billion in FY2026, with a ¥13.0 billion benefit expected in 2026. Medical innovation delivered ¥11.5 billion of benefit in FY2025, with ¥10.0 billion targeted for 2026 |
| Jul 2025 | Utsunomiya lithography plant completed | About ¥50 billion investment to raise lithography capacity, including NIL |
| 2,026 | Lithography capacity expansion | Capacity to rise more than 20% in 2027. Press reports (October 2026) say Canon plans to raise 2027 output to 1.5–2 times the 2026 level |
| Nov 2025 – Apr 2026 | Canon Electronics taken private | Group consolidation; acceleration of the space business |
| Dec 2025 | IFRS adoption from Q1 FY2027 | To improve the quality and international comparability of reporting |
| Dec 2025 – Apr 2026 | Medical integration | Absorption-type company split; assets of ¥263.2 billion and liabilities of ¥105.3 billion transferred (as of 31 December 2024) |
| Oct 2026 – Jan 2027 | Absorption of Canon Electron Tubes & Devices | Unifies the medical component business under the parent company |
| 2024–2026 | Heidelberg sheet-fed inkjet co-operation | Jetfire 50 (B3) and Jetfire 75 (B2) sold globally by Heidelberg on Canon engines; Canon supplies spare parts and consumables |
| 2024–2027 | Nanoimprint commercialisation | Tools at TIE and at a major chipmaker under production-wafer evaluation; mass-production adoption targeted from 2027; aim of 10–20 units a year within three to five years of the first shipment |
| Ongoing | PSI (production–sales–inventory) optimisation project | Led by the CFO's office; target of fewer than 60 inventory days |
| 2,026 | Shareholder returns | ¥200 billion buyback (completed September 2026); ¥160 dividend maintained |
| Ongoing | Sustainability | SBTi-validated 2030 targets: −42% Scope 1+2 and −25% Scope 3 (categories 1 and 11) against 2022; net-zero life-cycle GHG by 2050 |
FY2024–FY2026: Initiative: Structural reform programme; Detail / targets: Sales reform cost ¥22.0 billion in FY2025 and ¥17.2 billion in FY2026, with a ¥11.5 billion benefit expected in 2026. Production reform cost ¥14.7 billion in FY2025 and ¥14.2 billion in FY2026, with a ¥13.0 billion benefit expected in 2026. Medical innovation delivered ¥11.5 billion of benefit in FY2025, with ¥10.0 billion targeted for 2026
Jul 2025: Initiative: Utsunomiya lithography plant completed; Detail / targets: About ¥50 billion investment to raise lithography capacity, including NIL
2026: Initiative: Lithography capacity expansion; Detail / targets: Capacity to rise more than 20% in 2027. Press reports (October 2026) say Canon plans to raise 2027 output to 1.5–2 times the 2026 level
Nov 2025 – Apr 2026: Initiative: Canon Electronics taken private; Detail / targets: Group consolidation; acceleration of the space business
Dec 2025: Initiative: IFRS adoption from Q1 FY2027; Detail / targets: To improve the quality and international comparability of reporting
Dec 2025 – Apr 2026: Initiative: Medical integration; Detail / targets: Absorption-type company split; assets of ¥263.2 billion and liabilities of ¥105.3 billion transferred (as of 31 December 2024)
Oct 2026 – Jan 2027: Initiative: Absorption of Canon Electron Tubes & Devices; Detail / targets: Unifies the medical component business under the parent company
2024–2026: Initiative: Heidelberg sheet-fed inkjet co-operation; Detail / targets: Jetfire 50 (B3) and Jetfire 75 (B2) sold globally by Heidelberg on Canon engines; Canon supplies spare parts and consumables
2024–2027: Initiative: Nanoimprint commercialisation; Detail / targets: Tools at TIE and at a major chipmaker under production-wafer evaluation; mass-production adoption targeted from 2027; aim of 10–20 units a year within three to five years of the first shipment
Ongoing: Initiative: PSI (production–sales–inventory) optimisation project; Detail / targets: Led by the CFO's office; target of fewer than 60 inventory days
2026: Initiative: Shareholder returns; Detail / targets: ¥200 billion buyback (completed September 2026); ¥160 dividend maintained
Ongoing: Initiative: Sustainability; Detail / targets: SBTi-validated 2030 targets: −42% Scope 1+2 and −25% Scope 3 (categories 1 and 11) against 2022; net-zero life-cycle GHG by 2050
Products & Services
Printing
| Product line / brand | Description and key capabilities | Target customer | Notes / flagship |
|---|---|---|---|
| imageRUNNER ADVANCE DX (office MFDs) | Colour and monochrome A3/A4 MFDs with uniFLOW integration, cloud connectivity and security features | Corporates, SMBs, public sector | Core of the office annuity base; sold direct and through dealers, often under managed-print contracts |
| imageCLASS / i-SENSYS (laser printers and A4 MFDs) | Desktop laser printers and small MFDs | SMBs, home offices | High-volume toner annuity |
| PIXMA / MAXIFY / MegaTank inkjet | Consumer and small-office inkjet printers, including refillable ink-tank models | Consumers, SOHO | Ink-tank models target emerging markets and high-volume users |
| imagePRESS (sheet-fed toner production) | Colour toner production presses for commercial printing | In-plant and commercial printers | V-series and C-series models |
| varioPRINT iX-series (sheet-fed inkjet) | B3 sheet-fed inkjet presses using Canon piezo heads; basis of Heidelberg's Jetfire 50 | Commercial printers moving from offset | varioPRINT iX3200 is the engine of the Jetfire 50 |
| varioPress iV7 (B2 sheet-fed inkjet) | B2 inkjet press, 750 × 615 mm sheet, 1,200 dpi Canon piezo heads, up to 8,700 sheets per hour simplex; basis of Heidelberg's Jetfire 75 | Commercial printers | Introduced at Hunkeler Innovationdays 2025; Heidelberg deliveries from early 2026 |
| ProStream / ColorStream (continuous-feed inkjet) | Web-fed inkjet presses for books, direct mail and transactional print | Book printers, transactional and direct-mail printers | Legacy Océ franchise |
| varioPRINT 6000 TITAN (monochrome cut-sheet) | High-volume monochrome production printing | Transactional, book, in-plant printers | — |
| Colorado / Arizona (large-format and graphics) | UVgel roll-to-roll and flatbed printers | Sign and display, graphics | UVgel is proprietary Canon technology |
| imagePROGRAF (large-format technical and graphic inkjet) | Wide-format printers for CAD, GIS, posters and fine art | AEC firms, photographers, print shops | — |
| PRISMA / uniFLOW software | Production workflow (PRISMAsync, PRISMAprepare) and output management and secure print (uniFLOW) | Print service providers, enterprises | Software and services layer |
| imageFORMULA (document scanners) | Production and desktop document scanners | Enterprises, BPO firms | Reported partly in Others |
| Calculators | Office and scientific calculators | Consumers, schools | — |
Pricing is through list and lease pricing for hardware plus cost-per-page, managed-services and consumables contracts. Contract terms are not disclosed.
Medical
| Product line | Description and key capabilities | Target customer | Notes / flagship |
|---|---|---|---|
| CT (Aquilion family) | Multi-slice and wide-detector CT with AI-driven reconstruction; photon-counting CT in development using Redlen CZT detectors | Hospitals, imaging centres | Photon-counting CT is a named Phase VII priority |
| MRI (Vantage family) | 1.5 T and 3 T MRI with deep-learning reconstruction | Hospitals | — |
| Ultrasound (Aplio and Xario families) | General imaging, cardiovascular and women's-health ultrasound | Hospitals, clinics | — |
| X-ray and interventional (Alphenix and others) | Diagnostic X-ray, angiography and fluoroscopy | Hospitals | — |
| Digital radiography (CXDI) | Wireless flat-panel detectors | Hospitals, clinics, veterinary | Canon's original medical franchise |
| Ophthalmic | Retinal cameras, OCT, tonometers | Ophthalmologists, optometrists | — |
| In-vitro diagnostics | Clinical chemistry analysers and reagents | Laboratories | Reagents provide recurring revenue |
| Healthcare IT | Image management, AI diagnostic support, enterprise imaging | Hospitals | AI diagnostic support is a Phase VII focus |
| Components (Canon Electron Tubes & Devices) | X-ray tubes, flat-panel detectors and other imaging components | Internal use and OEMs | To be merged into Canon Inc. on 1 January 2027 |
Imaging
| Product line | Description and key capabilities | Target customer | Notes / flagship |
|---|---|---|---|
| EOS R full-frame mirrorless | Full-frame bodies including EOS R1 (flagship), EOS R5 Mark II and EOS R6 Mark III | Professionals, enthusiasts | EOS R6 Mark III lifted average selling prices in 2026 |
| EOS R APS-C mirrorless | EOS R7, R10, R50, R100 and R50 V (creator-oriented) | Enthusiasts, entry users, creators | — |
| RF / RF-S lenses | Full-frame and APS-C mirrorless lenses, including L-series and power-zoom video lenses | All ILC users | — |
| PowerShot compacts | Compact cameras, including the vlogging-oriented PowerShot V1 | Consumers, creators | Compact sales are on track for more than 50% growth in 2026 |
| Cinema EOS / broadcast | Cinema cameras, CINE-SERVO and broadcast lenses | Film and TV production, broadcasters | — |
| Axis network cameras and devices | IP cameras, access control, network audio, analytics | Security integrators, enterprises, cities, retail | Global leader in network video |
| Milestone XProtect (VMS) | Open-platform video management software | Integrators, enterprises | Software and licence revenue |
| Canon network cameras and analytics (Japan) | Network cameras and video analytics for the domestic market | Japanese enterprises and public sector | — |
Industrial (semiconductor manufacturing ecosystem)
| Product | Type / key specification | Application | Notes |
|---|---|---|---|
| FPA-6300ES6a | KrF scanner, high resolution and productivity | Memory, logic front-end | KrF demand from memory makers drove 2026 pricing and mix |
| FPA-6300ESW | Wide-field KrF scanner | Full-size CMOS image sensors, large-die devices | — |
| FPA-3030EX6 | KrF stepper | IoT devices, smaller substrates | — |
| FPA-5550iZ2 | High-productivity, high-overlay i-line stepper | Memory, logic front-end | — |
| FPA-5550iX | Wide-field (50 × 50 mm), 0.5 µm i-line stepper | Full-frame image sensors, XR devices | Launched 2023 |
| FPA-3030i6 | i-line stepper for 200 mm and smaller wafers, newly developed lens | Power devices, compound semiconductors | Launched January 2025 |
| FPA-3030i5a | Low cost-of-ownership i-line stepper for small substrates | IoT, communications, automotive | Launched March 2021 |
| FPA-3030iWa | Low-NA i-line stepper | Power, IoT, 200 mm and smaller substrates | — |
| FPA-5520iV (HR / LF options) | i-line stepper for back-end processes, ≤1.0 µm resolution, 52 × 34 mm field, ≤150 nm overlay | Fan-out wafer-level packaging, advanced packaging for AI chips | Benefits from AI and HBM packaging investment |
| FPA-8000iW | i-line stepper for large panels at 1.0 µm resolution | Panel-level packaging | Canon's first lithography system for large-panel back-end processing |
| FPA-1200NZ2C | Nanoimprint lithography; minimum line width 14 nm (about 5 nm node equivalent) | Leading-edge memory and logic, research | Shipped to TIE in 2024; additional tool shipped June 2026; Canon targets mass-production adoption from 2027 |
| MPAsp-series (H1003H, H1003T, E903T, E813) | FPD lithography systems | LCD and OLED panel production for IT, smartphones and TVs | 33 units shipped in FY2025 |
| Canon Tokki evaporation systems | OLED vacuum evaporation production lines | OLED panel makers | Demand depends on panel capex cycles |
| Canon Anelva deposition | Sputtering and thin-film deposition equipment | Semiconductor (including HBM-related), electronic devices | HBM orders grew sharply in 2026 |
| Canon Machinery die bonders | Die-bonding equipment | Back-end assembly | — |
| Canon CPO Equipment Program | Certified pre-owned Canon photolithography tools, refurbished by Canon U.S.A. service engineers and sourced through Canon's global network | 150 mm and 200 mm fabs, MEMS, power devices, specialty fabs | Shorter delivery and installation times than new tools |
| Customer-Owned Equipment Repair and Refurbishment Program | Refurbishment, reconfiguration and performance optimisation of customers' existing Canon steppers | Fabs running legacy Canon fleets | Extends tool life; competes with third-party refurbishers |
| Field service, upgrades and spare parts | Installation, maintenance, relocation, options and parts for Canon lithography fleets | All installed-base customers | Recurring revenue stream within Industrial |
Lithography and refurbished-tool prices are not published. Revenue depends on unit volumes and mix, and Canon notes that KrF systems sell at higher prices than i-line tools.
Others & Corporate
| Product / business | Description | Notes |
|---|---|---|
| Handy terminals | Rugged mobile data terminals | Canon Electronics and others |
| Document scanners | Desktop and production scanners | — |
| Space business | Small satellites and components through Canon Electronics; backing for launch company Space One | A named mid- to long-term growth theme in Phase VII; Canon Electronics taken private in 2026 partly to accelerate it |
Financial Narrative
Margins and growth (%)
Revenue CAGR from FY2021 to FY2025 was 7.1%. Over the longer FY2020–FY2025 window, which starts from the pandemic trough of ¥3,160.2 billion, the CAGR was 7.9%.
Balance sheet
Canon's investor materials show the short-term/long-term split of interest-bearing debt for FY2021–FY2023 (long-term portion ¥276.1 billion, ¥121.0 billion and ¥131.1 billion) but do not break out FY2024–FY2025. At 30 June 2026 total debt stood at about ¥1,270 billion, funding the Canon Electronics squeeze-out and the ¥200 billion 2026 buyback. Cash was ¥731.9 billion at the end of June 2026.
Ratios
Canon tracks inventory turnover days rather than a full cash conversion cycle. Management targets fewer than 60 days of inventory by the end of 2026, but by mid-2026 it expected about 65 days at year end. Inventory was built up ahead of memory-price inflation and component shortages, and to support Industrial capacity growth. Group inventory days rose to about 80 by Q3 2026, with Medical at about 114 days because of the production disruption.
Commentary on trends, inflections and drivers
Revenue. Canon has set consecutive revenue records in FY2024 (¥4,509.8 billion) and FY2025 (¥4,624.7 billion), finally surpassing its pre-2008 peak. Growth in FY2021–FY2022 was a post-pandemic rebound helped by yen weakness. In FY2023–FY2025 the mix of growth shifted. Printing peaked in FY2024 (+7.5%) and declined slightly in FY2025 (−1.1%) as office hardware placements softened. Imaging became the main engine (+12.5% in FY2025), driven by full-frame mirrorless, compacts and Axis network cameras. Industrial grew steadily but modestly. The yen is a structural tailwind: the dollar averaged ¥149.71 in FY2025 and ¥158.57 in the first nine months of 2026. Canon's own FX-neutral analysis shows underlying 9M FY2026 sales slightly lower year on year.
Profitability. Gross margin has been held at 46–48% despite inflation in components, logistics and labour. Pre-impairment operating margin climbed from 8.0% in FY2021 to 9.8–9.9% in FY2024–FY2025. Drivers were mix (Imaging and Industrial margins of 16–20%), price increases, and sales-structure reforms that lowered the operating-expense ratio from 37.6% to 36.9% in FY2025. The FY2024 dip in reported profit came entirely from the non-cash ¥165.1 billion Medical goodwill impairment, which carried no tax benefit. Reported net income fell to ¥160.0 billion and the payout ratio rose to 92.4%. FY2025 net income of ¥332.1 billion was a record on a post-2008 basis, and EPS of ¥367.48 benefited further from a 6.5% fall in the average share count.
Tariffs and costs. Additional U.S. tariffs cost ¥45.4 billion in FY2025, of which ¥41.2 billion was recovered through pricing, leaving a net operating-profit hit of ¥31.3 billion. In 2026 refunds of additional U.S. tariffs added ¥58.0 billion to Q2 operating profit. Management now assumes a 12.5% additional tariff rate rather than 15%. Offsetting that, memory-chip price inflation costs about ¥50 billion in 2026, and Middle East disruption raised oil-linked materials, utilities and logistics costs. In H2 2026, shortages of printed circuit boards and electronic components caused by AI demand hit Medical production.
Balance sheet. Canon has moved from net cash of ¥80.4 billion at end-FY2021 to net debt of ¥360.2 billion at end-FY2025. This is a deliberate capital-allocation shift: ¥700 billion of buybacks across FY2022–FY2025, a further ¥200 billion in 2026, and the ¥49.2 billion tender-offer stage of the Canon Electronics buyout followed by a squeeze-out. Leverage is still modest at 0.52x net debt/EBITDA in FY2025, and interest coverage remains above 60x. The equity ratio has eased from 61.9% to 56.9%, consistent with management's push to lift ROE toward 15% by 2030.
Cash flow. Operating cash flow was unusually strong in FY2024 (¥606.8 billion) because of working-capital release, and normalised to ¥475.9 billion in FY2025. Capex has stepped up to ¥250–262 billion a year to fund the Utsunomiya lithography plant, Industrial capacity and automation-led reshoring. Free cash flow of ¥238.5 billion in FY2025 covered dividends (¥147.6 billion) but not the ¥300 billion buyback, which was partly debt-funded. For FY2026 Canon projects operating cash flow of about ¥600 billion, capex of ¥270 billion and free cash flow of ¥240 billion.
FY2026 year to date. Nine-month sales rose 4.0% to ¥3,433.4 billion and operating profit rose 8.4% to ¥327.7 billion. Net income rose 12.2% to ¥246.4 billion. Gross margin expanded to 48.5% from 46.9% as tariff refunds and yen weakness offset memory costs. The full-year guide was cut in October 2026 to sales of ¥4,766.0 billion, operating profit of ¥456.0 billion and net income of ¥333.0 billion, essentially flat on FY2025. The main reason is a ¥90 billion Medical sales shortfall.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Principal contents | Key group companies |
|---|---|---|
Printing | Office MFDs, laser printers, inkjet printers, production printing (continuous-feed and sheet-fed inkjet and toner presses), large-format printers, scanners, calculators, print software and services | Canon Inc., Canon Production Printing (Netherlands), Canon Finetech Nisca, overseas sales companies |
Medical | CT, MRI, ultrasound, X-ray, digital radiography, ophthalmic, IVD, healthcare IT | Canon Inc. (Medical business integrated April 2026), Canon Medical Systems (domestic sales and service), Canon Electron Tubes & Devices, Redlen Technologies |
Imaging | Interchangeable-lens and compact cameras, lenses, network cameras, VMS and analytics, camcorders, cinema, broadcast | Canon Inc., Axis AB, Milestone Systems, Oita Canon, Nagasaki Canon |
Industrial | Semiconductor lithography (i-line, KrF, NIL), FPD lithography, OLED evaporation equipment, vacuum thin-film deposition, die bonders | Canon Inc. (Optical Products Operations), Canon Tokki, Canon Anelva, Canon Machinery, Canon Semiconductor Equipment, Canon Nanotechnologies |
Others & Corporate | Handy terminals, document scanners, space business, corporate R&D and headquarters costs | Canon Electronics and others |
Segment net sales (JPY Bn)
| Segment net sales (JPY Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Printing | 2,346.1 | 2,522.7 | 2,494.4 |
Medical | 553.8 | 568.8 | 580.6 |
Imaging | 861.6 | 937.4 | 1,054.9 |
Industrial | 314.7 | 351.7 | 361.1 |
Others & Corporate | 208.8 | 233.7 | 237.1 |
Eliminations | -104.0 | -104.5 | -103.4 |
Total net sales | 4,181.0 | 4,509.8 | 4,624.7 |
Segment operating profit (JPY Bn)
| Segment operating profit (JPY Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Printing | 228.3 | 289.9 | 255.8 |
Medical | 31.6 | 24.7 | 32.8 |
Imaging | 145.6 | 151.3 | 172.9 |
Industrial | 58.6 | 68.9 | 62.5 |
Others & Corporate | -86.3 | -91.2 | -69.5 |
Eliminations | -2.4 | 1.3 | 0.9 |
Total operating profit (pre-impairment) | 375.4 | 444.9 | 455.4 |
Segment operating margin (%)
| Segment operating margin (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Printing | 9.7 | 11.5 | 10.3 |
Medical (pre-impairment) | 5.7 | 4.3 | 5.6 |
Imaging | 16.9 | 16.1 | 16.4 |
Industrial | 18.6 | 19.6 | 17.3 |
Segment sales growth (%)
| Segment sales growth (%) | FY2024 | FY2025 |
|---|---|---|
Printing | 7.5 | -1.1 |
Medical | 2.7 | 2.1 |
Imaging | 8.8 | 12.5 |
Industrial | 11.8 | 2.7 |
Others & Corporate | 11.9 | 1.4 |
Share of consolidated net sales (%)
| Share of consolidated net sales (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Printing | 56.1 | 55.9 | 53.9 |
Medical | 13.2 | 12.6 | 12.6 |
Imaging | 20.6 | 20.8 | 22.8 |
Industrial | 7.5 | 7.8 | 7.8 |
Others & Corporate | 5.0 | 5.2 | 5.1 |
Segment Revenue
| Segment | 9M FY2025 sales | 9M FY2026 sales | 9M FY2025 OP | 9M FY2026 OP | FY2026 projected sales | FY2026 projected OP |
|---|---|---|---|---|---|---|
Printing | 1,825.6 | 1,867.4 | 202.2 | 208.2 | 2,579.4 | 262.8 |
Medical | 412.2 | 407.4 | 18.2 | 10.8 | 522.7 | 3.6 |
Imaging | 726.4 | 847.6 | 108.4 | 144.4 | 1,190.7 | 191.6 |
Industrial | 245.2 | 218.9 | 40.0 | 30.1 | 338.6 | 58.6 |
Others & Corporate | 172.0 | 175.5 | -67.1 | -65.7 | 247.5 | -60.6 |
Total | 3,302.9 | 3,433.4 | 302.4 | 327.7 | 4,766.0 | 456.0 |
Operating Metrics (units)
| Industrial unit shipments (units) | FY2023 | FY2024 | FY2025 | FY2026 plan |
|---|---|---|---|---|
Semiconductor lithography — total | 187 | 233 | 234 | 221 |
of which KrF | — | 51 | 46 | 66 |
of which i-line | — | 182 | 188 | 155 |
FPD lithography | — | 27 | 33 | 20 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net sales (JPY Bn) | 3,513.4 | 4,031.4 | 4,181.0 | 4,509.8 | 4,624.7 |
Gross profit (JPY Bn) | 1,627.8 | 1,827.8 | 1,968.9 | 2,143.1 | 2,162.0 |
Operating profit, reported (JPY Bn) | 281.9 | 353.4 | 375.4 | 279.8 | 455.4 |
Operating profit excl. FY2024 impairment (JPY Bn) | 281.9 | 353.4 | 375.4 | 444.9 | 455.4 |
Depreciation & amortisation (JPY Bn) | 221.2 | 226.5 | 238.7 | 235.5 | 239.2 |
EBITDA, reported OP + D&A (JPY Bn) | 503.1 | 579.9 | 614.0 | 515.2 | 694.6 |
Income before income taxes (JPY Bn) | 302.7 | 352.4 | 390.8 | 301.2 | 482.1 |
Income tax expense (JPY Bn) | 71.9 | 92.4 | 106.3 | 118.3 | 123.9 |
Net income attributable to Canon Inc. (JPY Bn) | 214.7 | 244.0 | 264.5 | 160.0 | 332.1 |
EPS basic (JPY) | 205.35 | 236.71 | 264.20 | 165.53 | 367.48 |
EPS diluted (JPY) | 205.29 | 236.63 | 264.08 | 165.44 | 367.25 |
Dividend per share (JPY) | 100 | 120 | 140 | 155 | 160 |
Dividend payout ratio (%) | 48.7 | 50.3 | 52.6 | 92.4 | 42.9 |
Average shares outstanding, basic (millions) | 1,046 | 1,031 | 1,001 | 967 | 904 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth (%) | 11.2 | 14.7 | 3.7 | 7.9 | 2.5 |
Gross margin (%) | 46.3 | 45.3 | 47.1 | 47.5 | 46.7 |
Operating margin, reported (%) | 8.0 | 8.8 | 9.0 | 6.2 | 9.8 |
Operating margin excl. impairment (%) | 8.0 | 8.8 | 9.0 | 9.9 | 9.8 |
EBITDA margin, reported (%) | 14.3 | 14.4 | 14.7 | 11.4 | 15.0 |
Net margin (%) | 6.1 | 6.1 | 6.3 | 3.5 | 7.2 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (JPY Bn) | 4,750.9 | 5,095.5 | 5,416.6 | 5,766.2 | 6,135.0 |
Cash & cash equivalents (JPY Bn) | 401.4 | 362.1 | 401.3 | 501.6 | 586.0 |
Interest-bearing debt (JPY Bn) | 321.0 | 417.4 | 517.3 | 663.5 | 946.2 |
Short-term loans incl. current portion of long-term debt (JPY Bn) | 44.9 | 296.4 | 386.2 | — | — |
Net debt, negative = net cash (JPY Bn) | -80.4 | 55.3 | 116.0 | 161.9 | 360.2 |
Canon Inc. shareholders' equity (JPY Bn) | 2,873.8 | 3,113.1 | 3,353.0 | 3,380.3 | 3,491.8 |
Total equity incl. non-controlling interests (JPY Bn) | 3,098.4 | 3,349.0 | 3,605.7 | 3,645.1 | 3,774.1 |
Goodwill (JPY Bn) | 953.9 | 972.6 | 1,045.4 | 915.3 | 985.8 |
Other intangible assets (JPY Bn) | 301.8 | 281.0 | 274.9 | 275.4 | 259.7 |
Goodwill & intangibles (JPY Bn) | 1,255.6 | 1,253.6 | 1,320.3 | 1,190.6 | 1,245.5 |
Current assets (JPY Bn) | 1,878.3 | 2,155.9 | 2,224.1 | 2,450.1 | 2,617.0 |
Current liabilities (JPY Bn) | 1,060.8 | 1,365.4 | 1,439.2 | 1,546.3 | 1,704.1 |
Working capital (JPY Bn) | 817.5 | 790.6 | 784.9 | 903.8 | 913.0 |
Equity ratio (%) | 60.5 | 61.1 | 61.9 | 58.6 | 56.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (JPY Bn) | 451.0 | 262.6 | 451.2 | 606.8 | 475.9 |
Capital expenditure, tangible + intangible, accrual basis (JPY Bn) | 179.0 | 183.3 | 231.7 | 256.3 | 249.5 |
Purchases of fixed assets, cash basis (JPY Bn) | 177.4 | 188.5 | 230.3 | 237.0 | 262.2 |
Free cash flow, OCF + investing CF (JPY Bn) | 243.8 | 81.8 | 175.8 | 309.5 | 238.5 |
Dividends paid (JPY Bn) | 88.9 | 119.3 | 130.9 | 141.5 | 147.6 |
Share buybacks (JPY Bn) | 0.0 | 100.0 | 100.0 | 200.0 | 300.0 |
Cash acquisitions of businesses (JPY Bn) | 31.8 | 5.9 | 54.6 | 32.7 | 0.9 |
Total shareholder distributions (JPY Bn) | 88.9 | 219.3 | 230.9 | 341.5 | 447.6 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | 7.9 | 8.1 | 8.2 | 4.8 | 9.7 |
ROA (%) | 4.6 | 5.0 | 5.0 | 2.9 | 5.6 |
ROIC, NOPAT / (total equity + debt − cash) (%) | 7.1 | 7.7 | 7.3 | 4.5 | 8.2 |
Current ratio (x) | 1.77 | 1.58 | 1.55 | 1.58 | 1.54 |
Debt / Canon shareholders' equity (x) | 0.11 | 0.13 | 0.15 | 0.20 | 0.27 |
Net debt / EBITDA (x) | -0.16 | 0.10 | 0.19 | 0.31 | 0.52 |
Interest coverage, OP / interest expense (x) | 436 | 338 | 166 | 75 | 62 |
Asset turnover, sales / average assets (x) | 0.75 | 0.82 | 0.80 | 0.81 | 0.78 |
R&D / sales (%) | 8.2 | 7.6 | 7.9 | 7.5 | 7.3 |
Price-to-book (x) | 1.0 | 0.9 | 1.1 | 1.4 | 1.2 |
Income Statement
| 9-month P&L (JPY Bn) | 9M FY2025 | 9M FY2026 |
|---|---|---|
Net sales | 3,302.9 | 3,433.4 |
Gross profit | 1,547.7 | 1,666.9 |
Operating expenses | 1,245.3 | 1,339.2 |
Operating profit | 302.4 | 327.7 |
Income before income taxes | 314.1 | 358.4 |
Net income attributable to Canon Inc. | 219.6 | 246.4 |
Region net sales (JPY Bn)
| Region net sales (JPY Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Japan | 830.4 | 864.8 | 901.6 | 955.5 | 961.5 |
Americas | 968.8 | 1,255.4 | 1,312.4 | 1,429.2 | 1,489.6 |
Europe | 894.9 | 1,034.0 | 1,111.2 | 1,184.4 | 1,225.5 |
Asia & Oceania | 819.2 | 877.2 | 855.7 | 940.8 | 948.1 |
Total | 3,513.4 | 4,031.4 | 4,181.0 | 4,509.8 | 4,624.7 |
Regional growth (%)
| Regional growth (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Japan | 4.3 | 6.0 | 0.6 |
Americas | 4.5 | 8.9 | 4.2 |
Europe | 7.5 | 6.6 | 3.5 |
Asia & Oceania | -2.4 | 9.9 | 0.8 |
Share of net sales (%)
| Share of net sales (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Japan | 21.6 | 21.2 | 20.8 |
Americas | 31.4 | 31.7 | 32.2 |
Europe | 26.6 | 26.3 | 26.5 |
Asia & Oceania | 20.5 | 20.9 | 20.5 |
Valuation Snapshot
| Metric | Value |
|---|---|
Share price (TSE) | ¥4,607 (2 October 2026); ¥4,503 (18 September 2026) |
52-week range | ¥3,987 – ¥5,033 |
1-year price change to 2 October 2026 | +7.9% |
OTC ADR (CAJPY) | US$29.90 on 30 October 2026; +1.2% year to date |
Market capitalisation | About ¥3.9 tn |
Enterprise value | About ¥4.6 tn |
Beta (5-year) | 0.28 |
Post-results move | More than −5% on 28 October 2026 |
Valuation multiple (as of 2 October 2026) | Canon |
P/E, trailing (x) | 11.6 |
P/E, forward (x) | 13.7 |
EV/EBITDA (x) | 6.4 |
EV/Sales (x) | 0.99 |
P/B (x) | 1.06 |
Dividend yield (%) | 3.5 |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividend per share (JPY) | 100 | 120 | 140 | 155 | 160 |
Payout ratio (%) | 48.7 | 50.3 | 52.6 | 92.4 | 42.9 |
Dividends & Capital Returns
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share repurchases (JPY Bn) | 100 | 100 | 200 | 300 | 200 |
Credit Ratings
| Agency | Rating | Date |
|---|---|---|
S&P Global | A (long-term) / A-1 (short-term) | As of 1 April 2026 |
Rating and Investment Information (R&I) | AA | As of 1 April 2026 |
Analyst Conclusions
Management guidance (revised 27 October 2026)
| FY2026 projection (JPY Bn) | Previous (Jul 2026) | Current (Oct 2026) | FY2025 actual |
|---|---|---|---|
| Net sales | 4,800.0 | 4,766.0 | 4,624.7 |
| Gross profit | 2,268.0 | 2,253.0 | 2,162.0 |
| Operating profit | 465.0 | 456.0 | 455.4 |
| Income before income taxes | 492.0 | 483.0 | 482.1 |
| Net income attributable to Canon Inc. | 340.0 | 333.0 | 332.1 |
Net sales: Previous (Jul 2026): 4800.0; Current (Oct 2026): 4766.0; FY2025 actual: 4624.7
Gross profit: Previous (Jul 2026): 2268.0; Current (Oct 2026): 2253.0; FY2025 actual: 2162.0
Operating profit: Previous (Jul 2026): 465.0; Current (Oct 2026): 456.0; FY2025 actual: 455.4
Income before income taxes: Previous (Jul 2026): 492.0; Current (Oct 2026): 483.0; FY2025 actual: 482.1
Net income attributable to Canon Inc: Previous (Jul 2026): 340.0; Current (Oct 2026): 333.0; FY2025 actual: 332.1
Key assumptions:
FX: full-year average of ¥157.58/USD and ¥182.90/EUR; Q4 assumes ¥155/USD and ¥180/EUR.
Volumes: 2.75 million ILC units; 221 semiconductor lithography units, with Q4 at 87 units; 20 FPD units.
Medical: about ¥90 billion sales impact in 2026, with normalisation expected from Q2 2027.
Tariffs: a 12.5% additional U.S. tariff assumption.
Management says the issues behind the downward revisions in cameras and Industrial should be resolved next year, and that Q4 includes gains from asset sales and liquidations under the production reforms.
Consensus growth expectations
Consensus implies roughly mid-single-digit EPS growth for FY2026 on a lower share count. The forward P/E of about 13.7x against a trailing 11.6x suggests expectations for FY2027 earnings recovery are tempered. The FY2027 debate centres on the lithography ramp, Medical normalisation and the yen.
Bull case
-
Lithography supercycle. Memory-driven KrF demand, a guided Q4 of 87 units, a 1.5–2x production increase targeted for 2027 at the new Utsunomiya plant, and HBM deposition orders could lift Industrial back above its 19.6% FY2024 margin and support a re-rating of what is still treated as a conglomerate.
-
Medical recovery is mechanical. About ¥90 billion of 2026 sales were lost to supply problems, not demand. Normalisation from Q2 2027, plus about ¥10 billion a year of integration savings, could return Medical toward its ¥38.3 billion FY2026 initial plan.
-
Capital-return engine. ¥900 billion of buybacks since 2022, a 3.5% dividend yield and an explicit path to 15% ROE by 2030, with net debt/EBITDA still around 0.5x, give strong per-share compounding even with modest top-line growth.
Bear case
-
Earnings quality and visibility. FY2026 operating profit is flat only because of ¥58 billion of one-off tariff refunds and yen weakness. Underlying (FX-neutral) sales fell in 9M FY2026, and guidance has been revised four times in nine months.
-
Printing erosion. Printing operating profit fell 11.8% in FY2025, and the core profit pool faces a secular decline in office print volumes, rising component costs and competition in production print.
-
Execution and governance risk. The Medical integration has already caused disruption. NIL has missed several commercialisation timelines. Leadership remains concentrated in executives aged 77–91, which raises key-person and strategic-agility risk while leverage rises.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Late Jan 2027 | FY2026 results; FY2027 guidance; new buyback framework; lithography unit plan for 2027 |
| 1 Jan 2027 | Merger with Canon Electron Tubes & Devices takes effect |
| Q1 FY2027 (Apr 2027) | First IFRS-based quarterly disclosure; restated comparatives |
| Q2 FY2027 | Expected normalisation of Medical production |
| 2,027 | First NIL mass-production adoption decision at a customer |
| Ongoing | Memory and PCB pricing and availability; U.S. tariff policy; USD/JPY and EUR/JPY |
| Ongoing | Heidelberg Jetfire 75 placements and commercial-print recovery |
| Mar 2027 | 126th AGM: board composition, succession, director-vote outcomes |
| Ongoing | Utsunomiya ramp; KrF/i-line mix; China export-control developments |
Late Jan 2027: Catalyst / monitorable: FY2026 results; FY2027 guidance; new buyback framework; lithography unit plan for 2027
1 Jan 2027: Catalyst / monitorable: Merger with Canon Electron Tubes & Devices takes effect
Q1 FY2027 (Apr 2027): Catalyst / monitorable: First IFRS-based quarterly disclosure; restated comparatives
Q2 FY2027: Catalyst / monitorable: Expected normalisation of Medical production
2027: Catalyst / monitorable: First NIL mass-production adoption decision at a customer
Ongoing: Catalyst / monitorable: Memory and PCB pricing and availability; U.S. tariff policy; USD/JPY and EUR/JPY
Ongoing: Catalyst / monitorable: Heidelberg Jetfire 75 placements and commercial-print recovery
Mar 2027: Catalyst / monitorable: 126th AGM: board composition, succession, director-vote outcomes
Ongoing: Catalyst / monitorable: Utsunomiya ramp; KrF/i-line mix; China export-control developments
Analyst verdict
Canon enters 2027 as a company whose reported numbers understate how much its portfolio has changed. Printing, still more than half of revenue, has peaked as a growth engine and is now best seen as a cash annuity managed for margin. The real swing factors sit in the smaller businesses. Imaging has become a 16% margin growth franchise on the back of full-frame mirrorless, a compact-camera revival and Axis network video. Industrial is small at 7.8% of sales, but it gives Canon a scarce, profitable exposure to mature-node and advanced-packaging lithography just as AI-driven memory and packaging capex accelerates. Canon's leadership in i-line steppers, its KrF gains with memory customers, the new Utsunomiya capacity and a real option on nanoimprint lithography make it a credible beneficiary of the semiconductor upcycle. Its OEM refurbishment and installed-base programmes also anchor it in the growing market for refurbished lithography.
The near-term picture is noisier. FY2026 operating profit guidance of ¥456 billion is essentially flat on FY2025. It depends on non-recurring tariff refunds and a weak yen, and it absorbs a ¥90 billion Medical supply shortfall that exposes the execution risk in the Medical integration. Rising leverage, funded buybacks and a concentrated, long-tenured leadership team call for a governance discount. The March 2026 handover of the presidency to Kazuto Ogawa is a first step, not a resolution.
At about 11–14x earnings, about 1.1x book and a 3.5% yield, the valuation already prices in little growth and accepts these risks. The investment case turns on three things in 2027: a lithography ramp toward management's 1.5–2x production ambition, Medical normalisation from Q2, and evidence that Phase VII margin targets (12% operating margin by 2028) can be met without FX help. If two of the three arrive, Canon's rating discount to diversified-technology peers should narrow. If they slip, the stock remains a dependable income vehicle rather than a compounder. On balance, Canon offers asymmetric but slow-burning upside, with the semiconductor-equipment franchise as the most underappreciated part of the group.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Born (age, Nov 2026) | Joined Canon | Prior roles / background | Shares held |
|---|---|---|---|---|---|
Fujio Mitarai | Representative Director, Chairman & CEO | 23 Sep 1935 (91) | 1961 | President from 1995; Chairman & CEO since 2006; also President 2012–2016 and 2020–2026; former Chairman of Keidanren. Educated at Chuo University (Law) | 153,144 |
Kazuto Ogawa | Representative Director, President & COO (from 27 Mar 2026) | 5 Apr 1958 (68) | 1981 | Executive Vice President; Group Executive, Global Marketing Strategy Headquarters | 7,500 |
Toshizo Tanaka | Representative Director, Vice Chairman & CFO | 8 Oct 1940 (86) | 1964 | Long-serving CFO; Senior General Manager, Corporate Governance Center; formerly Group Executive, Public Affairs and Sustainability | 25,810 |
Toshio Homma | Representative Director, Vice Chairman & CTO | 10 Mar 1949 (77) | 1972 | Formerly Executive Vice President & CTO and Head of the Printing Group | 83,052 |
Hiroaki Takeishi | Senior Managing Director; Head of Industrial Group | 20 Mar 1964 (62) | 1990 | Chairman & CEO of Canon Tokki; led NIL and lithography development | 10,600 |
Minoru Asada | Senior Managing Director; Group Executive, Finance & Accounting Headquarters; Chief, PSI Optimization Project | 18 Jun 1962 (64) | 1985 | Finance and accounting leadership | 11,579 |
Directors' Shareholdings
| Name | Born (age) | Background | Shares held |
|---|---|---|---|
Yusuke Kawamura | 5 Dec 1953 (72) | Former securities-industry economist, university professor and government council commissioner; on the board since 2021 | 3,100 |
Masayuki Ikegami | 29 Aug 1951 (75) | Former public prosecutor and Justice of the Supreme Court of Japan; attorney | 2,000 |
Masaki Suzuki | 18 Apr 1955 (71) | Former Ministry of Finance official, former Vice-Minister of the Environment, former Chairman of AEON Bank | 4,500 |
Akiko Ito | 28 Feb 1962 (64) | Former Ministry of Construction official; former Commissioner of the Consumer Affairs Agency | 1,600 |
Atsumi Arima | 11 Aug 1962 (64) | Former Mizuho Bank executive; outside director at several companies; newly elected March 2026 | 0 |
Executive Leadership Team — Ikuko Naruse
| Name | Status | Background |
|---|---|---|
Ikuko Naruse | Internal (new, March 2026) | Joined 1985; engineer in copiers and network-camera solutions |
Takeshi Morikawa | Internal | Canon career |
Yutaka Tanaka | Outside | — |
Yuka Shigetomi | Outside | First woman appointed as an outside A&SB member, 2025 |
Kaori Asakura | Outside (new, March 2026) | Senior Managing Director, Dai-ichi Life Research Institute; Dai-ichi Life holds about 1.4% of Canon |
Executive Leadership Team — Hideki Ozawa
| Name | Role |
|---|---|
Hideki Ozawa | Executive Vice President; Chairman & CEO, Canon (China) Co., Ltd. |
Seymour Liebman | Senior Managing Executive Officer, Canon Inc.; EVP, Chief Administrative Officer and General Counsel, Canon U.S.A. |
Toru Akakura | CEO, Canon Semiconductor Equipment Inc. |
Directors' Remuneration
| Item | Amount |
|---|---|
Bonus to six internal Directors for FY2025 (approved March 2026) | ¥581.1 million |
Bonus to Directors for FY2024 (approved March 2025) | ¥543.0 million |
Fujio Mitarai, total remuneration (FY2024 Annual Securities Report, individual disclosure) | ¥625 million |
Toshizo Tanaka, total remuneration (FY2024) | ¥270 million |
Toshio Homma, total remuneration (FY2024) | ¥259 million |
Kazuto Ogawa, total remuneration (FY2024) | ¥139 million |
Stock-type compensation stock options for Directors | Within a shareholder-approved annual cap; ceiling revised at the March 2024 AGM |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
29 Jan 2026 | Board resolves to change Representative Directors | "To further strengthen management structure" |
27 Mar 2026 | Kazuto Ogawa becomes Representative Director, President & COO; Atsumi Arima joins as outside Director; Ikuko Naruse and Kaori Asakura join the A&SB | Mitarai gives up the presidency he had resumed in 2020 |
1 Apr 2026 | Toshizo Tanaka becomes Vice Chairman & CFO; Toshio Homma becomes Vice Chairman & CTO | Alongside the Medical integration |
Mar 2023 | Akiko Ito appointed the first female Director | Followed the March 2022 AGM, when Mitarai's re-election received only about 50.6% approval amid proxy-adviser criticism of board diversity |
Major Shareholders
| Shareholder | Shares held (thousands) | Holding (%) |
|---|---|---|
The Master Trust Bank of Japan, Ltd. (Trust Account) | 154,586 | 17.6 |
Custody Bank of Japan, Ltd. (Trust Account) | 54,001 | 6.1 |
Mizuho Bank, Ltd. | 22,558 | 2.6 |
Moxley and Co. LLC (ADR depositary nominee) | 13,058 | 1.5 |
SMBC Nikko Securities Inc. | 12,750 | 1.5 |
JP Morgan Chase Bank 385781 | 12,395 | 1.4 |
State Street Bank and Trust Company 505001 | 12,193 | 1.4 |
The Dai-ichi Life Insurance Company, Limited | 12,120 | 1.4 |
JPMorgan Securities Japan Co., Ltd. | 11,981 | 1.4 |
Canon Group Employee Stock Ownership Association | 10,622 | 1.2 |
Competitive Landscape
Competitors by Segment
| Segment | Competitors | Canon's relative position |
|---|---|---|
Printing — office | Ricoh, Fujifilm Business Innovation, Konica Minolta, Kyocera Document Solutions, Sharp, Xerox, HP Inc. | Among the top office MFD vendors worldwide; broad dealer and direct footprint |
Printing — consumer and SOHO | HP Inc., Seiko Epson, Brother | Strong in inkjet and laser; competes in ink-tank models with Epson |
Printing — production | HP (Indigo, PageWide), Ricoh, Xerox, Konica Minolta, Kodak, Fujifilm, Screen | Leader in continuous-feed and sheet-fed inkjet (Océ heritage); Heidelberg alliance widens reach |
Medical | Siemens Healthineers, GE HealthCare, Philips, Fujifilm Healthcare, United Imaging | Strong in CT and ultrasound, especially in Japan; sub-scale globally against the "big three" |
Imaging — cameras | Sony, Nikon, Fujifilm, Panasonic, OM Digital Solutions, Ricoh (GR/Pentax), DJI | Long-standing global ILC market leader |
Imaging — network video | Hikvision, Dahua, Hanwha Vision, Motorola Solutions (Avigilon), Bosch | Axis is the leading non-Chinese network-camera brand; Milestone is a leading open VMS |
Industrial — lithography | ASML, Nikon, SMEE (China), EV Group and SUSS MicroTec (NIL and packaging), Onto Innovation (packaging) | Top share in i-line; strong in KrF; no presence in ArF or EUV |
Industrial — refurbished lithography | ASML (refurbished systems), Nikon (refurbished units), Ventex, independent refurbishers | Original-manufacturer refurbishment (CPO) for Canon fleets |
Industrial — deposition and display | Applied Materials, ULVAC, Tokyo Electron, Sunic | Canon Tokki is the leading OLED evaporation supplier; Anelva is a niche sputtering player |
Peer Comparison FY2026
| Company | Fiscal year | Revenue | Revenue growth (%) | Operating margin (%) | Net margin (%) |
|---|---|---|---|---|---|
Canon | FY Dec 2025 | ¥4,624.7 bn | 2.5 | 9.8 | 7.2 |
ASML | FY Dec 2025 | €32.7 bn | 15.6 | — | 29.4 |
Fujifilm Holdings | FY Mar 2026 | ¥3,357.0 bn | 5.0 | 10.4 | 8.2 |
Nikon | FY Mar 2026 | ¥677.2 bn | -5.3 | -16.6 | -12.7 |
Ricoh | FY Mar 2025 | ¥2,527.9 bn | 7.6 | 3.5 | 1.8 |
